Recent studies reveal significant advancements in the field of heart disease prevention, particularly through gene editing technologies. Eli Lilly has reported promising early results for its PCSK9 base editor, VERVE-102, which demonstrated a remarkable ability to reduce PCSK9 levels by up to 88% and LDL-C levels by up to 62%. These durable effects suggest the potential for a one-time treatment for hypercholesterolemia. The encouraging data has led Eli Lilly to prepare for the launch of Phase 2 trials, as the outcomes are comparable to current PCSK9 inhibitors. This innovative approach could revolutionize the management of cardiovascular diseases with a single-dose solution.